scholarly journals A Nuclear Receptor Corepressor–Dependent Pathway Mediates Suppression of Cytokine-Induced C-Reactive Protein Gene Expression by Liver X Receptor

2006 ◽  
Vol 99 (12) ◽  
Author(s):  
Florian Blaschke ◽  
Yasunori Takata ◽  
Evren Caglayan ◽  
Alan Collins ◽  
Peter Tontonoz ◽  
...  
PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e86342 ◽  
Author(s):  
Jagannath Misra ◽  
Dipanjan Chanda ◽  
Don-Kyu Kim ◽  
Seung-Rye Cho ◽  
Seung-Hoi Koo ◽  
...  

2008 ◽  
Vol 180 (5) ◽  
pp. 3492-3501 ◽  
Author(s):  
Teppei Nishikawa ◽  
Keisuke Hagihara ◽  
Satoshi Serada ◽  
Tomoyasu Isobe ◽  
Atsumi Matsumura ◽  
...  

1989 ◽  
Vol 8 (12) ◽  
pp. 3773-3779 ◽  
Author(s):  
U. Ganter ◽  
R. Arcone ◽  
C. Toniatti ◽  
G. Morrone ◽  
G. Ciliberto

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Kenji Inoue ◽  
Tatsuhiko Kodama ◽  
Hiroyuki Daida

Numerous studies have recently examined the role of pentraxin 3 (PTX3) in clinical situations. The pentraxin family includes C-reactive protein (CRP); however, unlike CRP, PTX3 is expressed predominantly in atherosclerotic lesions that involve macrophages, neutrophils, dendritic cells, or smooth muscle cells. Interestingly, PTX3 gene expression in human endothelial cells is suppressed to a greater extent by pitavastatin than the expression of 6,000 other human genes that have been examined, suggesting that PTX3 may be a novel biomarker for inflammatory cardiovascular disease. The expression and involvement of PTX3 in cardiovascular diseases are discussed in this paper, along with the characteristics of PTX3 that make it a suitable biomarker; namely, that the physiological concentration is known and it is independent of other risk factors. The results discussed in this paper suggest that further investigations into the potential novel use of PTX3 as a biomarker for inflammatory cardiovascular disease should be undertaken.


Sign in / Sign up

Export Citation Format

Share Document